pyrrolo(2,1-f)(1,2,4)triazine






10 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 15943473 Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J Med Chem 2005 Jun 16 1
2 16111887 New dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorg Med Chem Lett 2005 Nov 1 2
3 18072718 Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors. J Med Chem 2008 Jan 10 1
4 18221875 Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors. Bioorg Med Chem Lett 2008 Feb 15 2
5 18364256 Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors. Bioorg Med Chem Lett 2008 Apr 15 2
6 21705217 Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors. Bioorg Med Chem Lett 2011 Aug 1 1
7 21859094 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity. J Med Chem 2011 Sep 22 2
8 25139565 Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors. Bioorg Med Chem Lett 2014 Sep 15 1
9 30248654 Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2. Eur J Med Chem 2018 Oct 5 2
10 31670202 Corrigendum to 'Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2' [European journal of medicinal chemistry 158 (2018) 814-831]. Eur J Med Chem 2020 Jan 1 2